Practical issues in the development of argatroban: A perspective

Pathophysiology of Haemostasis and Thrombosis

Volumn 32, Issue SUPPL. 3, 2002, Pages 56-65

  Fareed, Jawed ^a,b   Hoppensteadt, Debra ^a   Iqbal, Omer ^a   Tobu, Mehmut ^a   Lewis, Bruce E ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Anticoagulant; Antithrombin; Reversible inhibitor; Thrombosis

Indexed keywords

ARGATROBAN; HIRUDIN; RECOMBINANT HIRUDIN;

ANTICOAGULATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INFUSION; DRUG INHIBITION; DRUG OVERDOSE; DRUG RESEARCH; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEMOFILTRATION; HUMAN; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT INDICATION;

ANIMALS; ANTICOAGULANTS; DRUG INTERACTIONS; HEMOSTASIS; HUMANS; PIPECOLIC ACIDS; RATS; THERAPEUTIC EQUIVALENCY; THROMBIN;

EID: 0345377860     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069110     Document Type: Review

References (30)

1. Fareed J, Lewis BE, Callas D, Hoppensteadt DA, Walenga JM, Bick RL: Antithrombin agents: The new class of anticoagulant and antithrombotic drugs. Clin Appl Thromb Hemost 1999;5(suppl 1):S45-S55.
2. Fareed J, Hoppensteadt DA, Bacher P, Messmore HL: Antithrombin agents: The new class of antithrombotic drugs; in Pifarre R, Scanlon PJ (eds): Evidence-Based Management of Acute Coronary Syndrome. Philadelphia, Hanley & Belfus, 2001, pp 131-146.
3. Fareed J, Callas D, Hoppensteadt DA, Lewis BE, Bick RL, Walenga JM: Antithrombin agents as anticoagulants and antithrombotics: Implications in drug development. Semin Hematol 1999;36:42-56.
4. Fareed J, Callas D, Hoppensteadt D, Jeske W, Walenga JM: Recent developments in antithrombotic agents. Exp Opin Invest Drugs 1995;4:389-412.
5. Fareed J, Hoppensteadt DA, Breddin HK: Current perspectives in antithrombotic therapy. Hämostaseologie 2001;21:78-85.
6. Fareed J, Hoppensteadt DA: Antithrombin and anti-Xa agents in the control of thrombogenesis. Pharmazie 2001:56(suppl 1):S12-S21.
7. Jeske W, Walenga JM, Lewis BE, Fareed J: Pharmacology of argatroban. Exp Opin Invest Drugs 1999;8:625-654.
8. Kaiser B, Callas D, Walenga JM, Fareed J: Synthetic and recombinant antithrombin drugs. Exp Opin Invest Drugs 1998;7:963-985.
9. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang IK, Rifkin SD, Moran J, Hursting MJ, Kelton JG, for the ARG-911 Study Investigators: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843.
10. Lewis BE, Ferguson JJ, Grassman ED, Fareed J, Walenga JM, Joffrion J, Wrona L, Johnson SA, Schwarz RP, McKiernan T: Successful coronary interventions performed with argatroban anticoagulation in patients with heparin-induced thrombocytopenia and thrombosis syndrome. J Invasive Cardiol 1996;8:410-417.
11. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, de Bono D, Ferguson J, Willerson JT, Strony J, Ganz P, et al: Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993;87:1622-1629.
12. Zawilska K, Zozulinska M, Turowiecka Z, Blahut M, Drobnik L, Vinazzer H: The effect of a long-acting recombinant hirudin (PEG-hirudin) on experimental disseminated intravascular coagulation (DIC) in rabbits. Thromb Res 1993;69:315-320.
13. Sakata Y, Curriden S, Lawrence D, Griffin JH, Loskutoff DJ: Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA 1985;82:1121-1125.
14. De Fouw NJ, van Hinsberg VW, de Jong YF, Haverkate F, Bertina RM: The interaction of activated protein C and thrombin with the plasminogen activator inhibitor released from human endothelial cells. Thromb Haemost 1987;57:176-182.
15. Dichek D, Quertermous T: Thrombin regulation of mRNA levels of tissue plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Blood 1989;74:222-228.
16. Collen D, Lijnen HR, Todd PA, Goa KL: Tissue-type plasminogen activator: A review of its pharmacology and therapeutic use as a thrombolytic agent. Drugs 1989;38:346-388.
17. Hoylaerts M, Rijken D, Lijnen HR, Collen D: Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982;257:2912-2919.
18. Coleman RW: Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun 1968;35:273-279.
19. Goldsmith GH, Saito H, Ratnoff OD: The activation of plasminogen by Hageman factor fragments. J Clin Invest 1978;62:54-60.
20. Barabas E, Szell E, Bajusz S: Screening for fibrinolysis inhibitory effect of synthetic thrombin inhibitors. Blood Coagul Fibrinolysis 1993;4: 243-248.
21. Callas D, Bacher P, Iqbal O, Hoppensteadt D, Fareed J: Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin. Thromb Res 1994;74:193-205.
22. Gilboa N, Villannueva GB, Fenton JW II: Inhibition of fibrinolytic enzymes by thrombin inhibitors. Enzyme 1988;40:144-148.
23. Dodt J, Kohler S, Schmitz T, Wilhelm B: Distinct binding sites of Ala 48-hirudin 1-47 and Ala 48-hirudin 48-65 on α thrombin. J Biol Chem 1990;265:713-718.
24. Petersen TE, Roberts HR, Sottrup-Jensen L, Magnusson S: Primary structure of hirudin, a thrombin-specific inhibitor; in Peters H (ed): Peptides of the Biological Fluids. Oxford, Pergamon, 1976, pp 145-149.
25. Scharf M, Engels J, Tripier D: Primary structures of new 'isohirudins'. FEBS Lett 1989;225:105-110.
26. Okamoto S, Hijikata A, Kikumoto R, Tonomura S, Hara H, Ninomiya K, Maruyama A, Sugano M, Tamao Y: Potent inhibition of thrombin by the newly synthesized derivative No. 805. The importance of stereo structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981;101:440-446.
27. Walenga JM, Jeske WP, Wood JJ, Ahmad S, Lewis BE, Bakhos M: Laboratory tests for heparin-induced thrombocytopenia: A multicenter study. Semin Hematol 1999;36(suppl 1):22-28.
28. Walenga JM, Ahmad S, Hoppensteadt D, Iqbal O, Hursting MJ, Lewis BE: Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 2002;105:401-405.
29. Ahmad S, Ahsan A, Iqbal O, Hoppensteadt DA, Lewis BE, Walenga JM, Fareed J: Pharmacokinetics and pharmacodynamics of argatroban as studied by HPLC and functional methods: Implications in the monitoring and dosage-optimizations in cardiovascular patients. Clin Appl Thromb Hemost 1998;4:243-249.
30. Callas D, Fareed J: Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method. Thromb Res 1996;83:463-468.